Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/delimiting-and-delivering-promontory-cofounder-cant-hire-fast-enough-small-biotech-expands
https://www.prnewswire.com/news-releases/phosplatin-therapeutics-adopts-new-corporate-name-as-promontory-therapeutics-inc-301540328.html
https://www.clinicaltrialsarena.com/news/phosplatin-thymic-epithelial-tumour/
https://www.prnewswire.com/news-releases/phosplatin-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-trial-of-pt-112-for-thymoma-and-thymic-carcinoma-in-collaboration-with-national-cancer-institute-301524327.html
https://www.prnewswire.com/news-releases/phosplatin-therapeutics-appoints-lorenzo-galluzzi-phd-a-pioneer-in-immunogenic-cell-death-research-to-scientific-advisory-board-301509599.html
https://www.prnewswire.com/news-releases/phosplatin-therapeutics-presents-on-pt-112-at-the-2022-aacr-annual-meeting-selective-intracellular-effects-leading-to-immunogenic-cell-death-icd-in-prostate-cancer-cell-models-301499763.html
https://www.prnewswire.com/news-releases/phosplatin-therapeutics-to-present-at-2021-bio-digital-301309749.html
https://www.prnewswire.com/news-releases/phosplatin-therapeutics-reports-phase-1b-study-results-of-immunogenic-cell-death-inducer-pt-112-plus-pd-l1-inhibitor-avelumab-in-metastatic-prostate-cancer-at-asco-annual-meeting-301296485.html
https://www.prnewswire.com/news-releases/phosplatin-therapeutics-presents-phase-i-dose-escalation-data-of-pt-112-in-patients-with-relapsed--refractory-multiple-myeloma-at-ash-annual-meeting-301186983.html
https://www.prnewswire.com/news-releases/phosplatin-therapeutics-announces-data-revealing-novel-mechanistic-attributes-for-pt-112-at-the-32nd-eortc-nci-aacr-virtual-symposium-301160304.html